# Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

> **NCT04345367** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 727 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Abrocitinib 200 mg
- **COMBINATION_PRODUCT:** Dupilumab 300 mg

## Key facts

- **NCT ID:** NCT04345367
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-11
- **Primary completion:** 2021-07-13
- **Final completion:** 2021-07-13
- **Target enrollment:** 727 (ACTUAL)
- **Last updated:** 2022-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04345367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04345367, "Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04345367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*